Durect (NASDAQ:DRRX) Stock

Durect

Durect Corp is a biopharmaceutical company. It is engaged in the research, development, and manufacturing of pharmaceutical products. The company develops pharmaceutical products based on two categories which include new chemical entities and proprietary pharmaceutical programs. The company's pipeline products consist of DUR-928, POSIMIR, and others. Geographically, the company operates in the United States, Europe, Japan, and other countries, of which key revenue is derived from the Europe .

Long Ideas

News

Penny Stocks

Pre-Market Outlook

Markets

Trading Ideas

AADI

DRRX

Kintara Therapeutics, Inc. - Common Stock

KTRA

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 3 Health Care Stocks That Are Preparing To Pump This Month

Earnings

Eurozone

Commodities

Small Cap

Global

Intraday Update

BLDE

ESTA

FTCI

REAL

U.S. stocks traded mostly lower toward the end of trading, with the Dow Jones falling around 80 points on Wednesday

The Dow traded down 0.23% to 34,074.30 while the NASDAQ fell 0.01% to 13,638.07. The S&amp;P 500 also fell, dropping, 0.01% to 4,378.16.

Crude Oil Falls 2.5%; Ralph Lauren Posts Upbeat Earnings

Movers

ADNT

AGTI

APEI

ARRY

AVDX

CAUD

CPNG

CREV

CTOS

EBAY

ENVX

EOLS

EXFY

FLYW

GPRO

HEAR

HOOD

HSCS

INSP

JGGC

KIND

LEJU

LIFW

LUMO

MGIC

MOBV

MRCY

MRVI

NCMI

NRDY

NVEI

NVOS

OSCR

PBLA

PEGY

PRCH

RBLX

RILY

SHLS

SNBR

SOPA

THAR

TOST

UONE

UPST

UPWK

WISH

WLDS

WRBY

Gainers


	Heart Test Laboratories, Inc. (NASDAQ: HSCS) shares climbed 96% to $0.2921 after falling over 7% on Tuesday.


Why Toast Shares Are Trading Lower By Around 17%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

Durect Corp

DURECT Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRRX#NASDAQ">DRRX</a>), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury, today announced the sale of its ALZET&#xAE; line of osmotic pumps to Lafayette Instrument Co. (LIC), a portfolio company of Branford Castle Partners II, L.P., a North-American focused private equity firm.
<a href="https://mma.prnewswire.com/media/81466/DURECT_LOGO_2023.html">www.durect.com</a>) is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer." alt="DURECT Corporation (<a href="http://www.durect.com/">www.durect.com</a>) is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer."&gt;
Under the terms of the agreement, LIC paid&nbsp;DURECT&nbsp;$17.5 million in exchange for certain assets and liabilities associated with&nbsp;the ALZET&nbsp;product line. Simultaneous with this transaction, DURECT has paid off all remaining obligations under the term loan agreement with Oxford Finance LLC.&nbsp;

Asset Sales

DURECT Sells ALZET Osmotic Pumps for $17.5M, Pays Off Loan Obligations

HC Wainwright &amp; Co. analyst Ed Arce reiterates Durect (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRRX#NASDAQ">DRRX</a>) with a Neutral.

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Neutral on Durect

Durect (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRRX#NASDAQ">DRRX</a>) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.17) by 17.65 percent. The company reported quarterly sales of $1.927 million which missed the analyst consensus estimate of $1.975 million by 2.43 percent. This is a 10.49 percent increase over sales of $1.744 million the same period last year.

Earnings Beats

Earnings Misses

Durect Q3 2024 GAAP EPS $(0.14) Beats $(0.17) Estimate, Sales $1.927M Miss $1.975M Estimate

ACXP

ADAP

AEMD

AFCG

AFYA

AGRO

AIRJ

ALUR

ALVO

ARCO

ATEX

AYTU

BCDA

BETR

BFRI

BITF

Bakkt Holdings, Inc. Class A Common Stock

BKKT

BNGO

BOXL

BRFS

BWEN

CAAS

CAPR

CREX

CRNT

CSAN

CSCO

CSLR

CSTE

CYBR

DADA

DGII

DMAC

DOLE

DTCK

ECOR

EDBL

ENLT

EZPW

FORA

FPAY

FULC

GILT

GLAD

GOEV

GRYP

HIVE

HROW

HYZN

IBTA

ICAD

ICCC

INLX

INVZ

JAGX

JJSF

KBDC

KLIC

KMDA

KRMD

KULR

LMFA

LOAR

LQDA

LUCD

LVLU

MCRB

MPTI

MRSN

NTWK

NXGL

OMER

OPRX

OTRK

OWLT

OXBR

PAVM

PCYO

Earnings Scheduled For November 13, 2024

Durect (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRRX#NASDAQ">DRRX</a>) is preparing to release its quarterly earnings on Wednesday, 2024-11-13. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Durect to report an earnings per share (EPS) of $-0.17.
Anticipation surrounds Durect's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Earnings History Snapshot</h3>
Last quarter the company beat EPS by $0.05, which was followed by a 5.67% drop in the share price the next day.
Here's a look at Durect's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.17</td>
<td>-0.22</td>
<td>-0.33</td>
<td>-0.42</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.12</td>
<td>-0.25</td>
<td>-0.10</td>
<td>-0.14</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-6.0%</td>
<td>-14.000000000000002%</td>
<td>-10.0%</td>
<td>3.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1731438341_0.png" alt="eps graph" />
<h3>Tracking Durect's Stock Performance</h3>
Shares of Durect were trading at $1.29 as of November 11. Over the last 52-week period, shares are up 111.48%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/DRRX/earnings">To track all earnings releases for Durect visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

An Overview of Durect's Earnings

Durect (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRRX#NASDAQ">DRRX</a>) will release its quarterly earnings report on Wednesday, 2024-11-13. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Durect to report an earnings per share (EPS) of $-0.17.
Durect bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Earnings History Snapshot</h3>
Last quarter the company beat EPS by $0.05, which was followed by a 5.67% drop in the share price the next day.
Here's a look at Durect's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.17</td>
<td>-0.22</td>
<td>-0.33</td>
<td>-0.42</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.12</td>
<td>-0.25</td>
<td>-0.10</td>
<td>-0.14</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-6.0%</td>
<td>-14.000000000000002%</td>
<td>-10.0%</td>
<td>3.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1731435381_0.png" alt="eps graph" />
<h3>Performance of Durect Shares</h3>
Shares of Durect were trading at $1.29 as of November 11. Over the last 52-week period, shares are up 111.48%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/DRRX/earnings">To track all earnings releases for Durect visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Preview: Durect

Biotech

General

DURECT Announces Phase 3 Registrational Trial Design For Larsucosterol In Alcohol-Associated Hepatitis; Type B Meeting With FDA Held Under Breakthrough Therapy Designatoin Resulted In Agreement On Aspects Of Phase 3 Design, Says Single Phase 3 Trial Designed To Enroll 200 U.S. Patients With A 90-day Survival Primary Endpoint; Topline Results Expected Within Two Years Of Trial Initiation

Durect (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRRX#NASDAQ">DRRX</a>) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.17) by 29.41 percent. The company reported quarterly sales of $2.171 million which missed the analyst consensus estimate of $2.492 million by 12.87 percent. This is a 4.32 percent increase over sales of $2.081 million the same period last year.

Durect Q2 2024 GAAP EPS $(0.12) Beats $(0.17) Estimate, Sales $2.171M Miss $2.492M Estimate

<h3>Gainers</h3>
<ul>
<li>Rezolute (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RZLT#NASDAQ">RZLT</a>) stock increased by 52.7% to $4.58 during Tuesday's after-market session. The company's market cap stands at $183.8 million. The company's, Q3 earnings came out 4 days ago. </li>
<li>Mustang Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBIO#NASDAQ">MBIO</a>) stock increased by 30.64% to $0.41. The company's market cap stands at $5.0 million. The company's, Q1 earnings came out 4 days ago. </li>
<li>Qilian Intl Hldg Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QLI#NASDAQ">QLI</a>) shares rose 14.77% to $0.87. The company's market cap stands at $31.1 million. </li>
<li>MyMD Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYMD#NASDAQ">MYMD</a>) shares increased by 12.68% to $2.31. The market value of their outstanding shares is at $4.9 million. The company's, Q4 earnings came out 4 days ago. </li>
<li>Immunome (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNM#NASDAQ">IMNM</a>) shares moved upwards by 7.39% to $14.66. The market value of their outstanding shares is at $879.1 million. </li>
<li>Acurx Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACXP#NASDAQ">ACXP</a>) shares rose 7.35% to $2.92. The company's market cap stands at $46.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Durect (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRRX#NASDAQ">DRRX</a>) shares decreased by 13.2% to $1.12 during Tuesday's after-market session. The market value of their outstanding shares is at $34.7 million. </li>
<li>Cingulate (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CING#NASDAQ">CING</a>) shares decreased by 10.1% to $0.75. The company's market cap stands at $4.5 million. </li>
<li>Haemonetics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAE#NYSE">HAE</a>) shares decreased by 8.79% to $85.0. The market value of their outstanding shares is at $4.3 billion. </li>
<li>LifeStance Health Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFST#NASDAQ">LFST</a>) stock fell 7.36% to $6.93. The market value of their outstanding shares is at $2.6 billion. </li>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) shares fell 7.27% to $2.17. The company's market cap stands at $9.5 million. </li>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) stock fell 6.16% to $0.24. The market value of their outstanding shares is at $4.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BDRX

CING

IMNM

LFST

MBIO

MyMD Pharmaceuticals, Inc. - Common Stock

MYMD

NUWE

RZLT

12 Health Care Stocks Moving In Tuesday's After-Market Session

Rumors

Watching DURECT; Traders Circulate Unconfirmed Analyst Comments Suggesting A $5 PT on The Stock After FDA Feedback

<h3>Gainers</h3>
<ul>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) shares increased by 67.7% to $2.13 during Tuesday's pre-market session. The market value of their outstanding shares is at $9.3 million. </li>
<li>Durect (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRRX#NASDAQ">DRRX</a>) stock rose 23.07% to $1.28. The market value of their outstanding shares is at $39.7 million. </li>
<li>Larimar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRMR#NASDAQ">LRMR</a>) stock rose 17.33% to $8.53. The market value of their outstanding shares is at $544.2 million. </li>
<li>Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) shares moved upwards by 16.64% to $0.91. The market value of their outstanding shares is at $149.7 million. </li>
<li>Envoy Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COCH#NASDAQ">COCH</a>) shares rose 14.81% to $3.72. The company's market cap stands at $72.9 million. As per the news, the Q1 earnings report came out 4 days ago. </li>
<li>Citius Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTXR#NASDAQ">CTXR</a>) shares increased by 14.62% to $0.76. The market value of their outstanding shares is at $136.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Scorpius Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SCPX#AMEX">SCPX</a>) stock decreased by 21.9% to $0.12 during Tuesday's pre-market session. The market value of their outstanding shares is at $8.2 million. </li>
<li>Orgenesis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORGS#NASDAQ">ORGS</a>) stock decreased by 16.31% to $0.46. The company's market cap stands at $15.8 million. </li>
<li>SINTX Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) stock decreased by 15.68% to $0.1. The company's market cap stands at $11.6 million. </li>
<li>Kazia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KZIA#NASDAQ">KZIA</a>) stock fell 15.28% to $0.23. The market value of their outstanding shares is at $6.1 million. </li>
<li>NovaBay Pharmaceuticals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NBY#AMEX">NBY</a>) shares decreased by 13.77% to $0.15. The company's market cap stands at $5.6 million. </li>
<li>Akanda (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAN#NASDAQ">AKAN</a>) stock declined by 12.12% to $0.12. The company's market cap stands at $4.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

Durect

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga